All In Biotech

Drug Trial Radar · NCT07182708

High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

High-dose Firmonertinib Combined With Bevacizumab as Neoadjuvant Therapy in Stage II-IIIB, Resectable, EGFR-mutated Non-small Cell Lung Cancer Patients: A Single-arm, Multi-center, Open-label Phase II Clinical Study

Last checked: Nov 19, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

Oct 1, 2025

Primary completion

Dec 30, 2029

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Peking University Cancer Hospital & InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, single-arm, open-label, multicenter clinical study aimed at evaluating the efficacy and safety of Firmonertinib 160 mg combined with Bevacizumab as neoadjuvant therapy in patients with resectable stage II-IIIB Epidermal Growth Factor Receptor(EGFR)-mutated non-small cell lung cancer.

Conditions

  • NSCLC (Non-small Cell Lung Cancer)
  • EGFR Activating Mutation
  • Resectable Lung Non-Small Cell Carcinoma

Interventions

  • Firmonertinib Mesilate TabletsDrug

    Firmonertinib Mesilate Oral administration 160 mg once daily for 3 months before surgery. Radical tumor resection will be performed at least 6 weeks after completion of Bevacizumab treatment. After surgery, the treatment plan was determined by the researchers, with options including Firmonertinib Mesilate Tablets: Oral administration once daily, 80mg per dose, for 3 years or until disease progression or intolerable toxicity occurs.

  • Bevacizumab injectionDrug

    Bevacizumab injection (intravenous infusion, 7.5 mg/kg) administered every 21 days as one cycle, for a total of 2 cycles. Radical tumor resection will be performed at least 6 weeks after completion of Bevacizumab treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. pathological Complete Response(pCR) rateTime frame: Within 24 hours after surgical resection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.